Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Melissa Ellen Hogg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5641-4438; OpenAlex author ID A5089302427. Sources: OpenAlex.

Their work

Papers
34 (first author 2, last author 10)
Trials
0
Grants
0
Labs led
3
Collaborators
96
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 3 papers · 2017: 4 papers · 2018: 4 papers · 2019: 2 papers · 2020: 7 papers · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 34

  1. Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. Co-author DOI 10.1002/jso.70179↗
  2. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  3. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  4. Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Mult… Last author DOI 10.1245/s10434-025-16916-7↗
  5. Robotic pancreas surgery for pancreatic cancer. Last author DOI 10.1097/js9.0000000000000906↗
  6. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  7. Extended postoperative thromboprophylaxis after pancreatic resection for pancreatic cancer is associated with decreased risk of venous thromboembolism in the m… Last author DOI 10.1002/jso.27135↗
  8. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2022.18355↗
  9. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict … Co-author DOI 10.1016/j.cgh.2020.11.041↗
  10. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Co-author DOI 10.1111/cts.13029↗
  11. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  12. A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Co-author DOI 10.1245/s10434-021-09594-8↗
  13. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10175-y↗
  14. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Co-author DOI 10.1158/1078-0432.ccr-19-4042↗
  15. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-019-08156-3↗
  16. Correction to: Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-020-08249-4↗
  17. ASO Author Reflections: Serum CA19-9 Utility in Pancreatic Adenocarcinoma in Patients Undergoing Neoadjuvant Therapy. First author DOI 10.1245/s10434-020-08342-8↗
  18. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08468-9↗
  19. SMAD4 Loss is Associated with Response to Neoadjuvant Chemotherapy with Hydroxychloroquine in Patients with Pancreatic Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-125334/v1↗
  20. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.19.21152↗
  21. Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.hpb.2018.10.012↗
  22. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection. Co-author DOI 10.1245/s10434-018-07148-z↗
  23. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.31628↗
  24. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally. Last author DOI 10.1245/s10434-018-6487-5↗
  25. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Last author DOI 10.1245/s10434-018-6521-7↗
  26. ASO Author Reflections: Health Disparities in Pancreatic Cancer. First author DOI 10.1245/s10434-018-6961-0↗
  27. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? Co-author DOI 10.1245/s10434-016-5707-0↗
  28. Failure to Treat: Audit of an Institutional Cancer Registry Database at a Large Comprehensive Cancer Center Reveals Factors Affecting the Treatment of Pancreat… Last author DOI 10.1245/s10434-017-5880-9↗
  29. Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival. Co-author DOI 10.1245/s10434-017-5975-3↗
  30. A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2017.04.02↗
  31. Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-instituti… Co-author DOI 10.1007/s11605-016-3256-2↗
  32. A pancreatic cancer multidisciplinary clinic: insights and outcomes. Last author DOI 10.1016/j.jss.2016.01.021↗
  33. Deviations from Expected Treatment of Pancreatic Cancer in Octogenarians: Analysis of Patient and Surgeon Factors. Last author DOI 10.1245/s10434-016-5456-0↗
  34. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-014-3842-z↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Herbert J. Zeh · 27 shared papers, 2014–2026 · strength 2.73
  2. Amer H. Zureikat · 26 shared papers, 2014–2026 · strength 2.67
  3. Nathan Bahary · 17 shared papers, 2014–2022 · strength 1.57
  4. Brian A. Boone · 12 shared papers, 2014–2026 · strength 1.44
  5. Aatur Dilip Singhi · 11 shared papers, 2014–2022 · strength 1.09
  6. Alessandro Paniccia · 6 shared papers, 2021–2026 · strength 0.87
  7. Sarah B. Hays · 3 shared papers, 2024–2026 · strength 0.79
  8. Amr I. Al Abbas · 6 shared papers, 2018–2020 · strength 0.77
  9. Caroline J. Rieser · 6 shared papers, 2018–2025 · strength 0.70
  10. Asmita Chopra · 4 shared papers, 2021–2026 · strength 0.67
  11. Ahmad B. Hamad · 6 shared papers, 2017–2020 · strength 0.59
  12. Michael T. Lotze · 5 shared papers, 2020–2021 · strength 0.54
  13. David L. Bartlett · 6 shared papers, 2014–2021 · strength 0.53
  14. Patricio Marcelo Polanco · 2 shared papers, 2025–2026 · strength 0.42
  15. Emile Farah · 2 shared papers, 2025–2026 · strength 0.42
  16. Mark S. Talamonti · 2 shared papers, 2025–2026 · strength 0.42
  17. Jae Pil Jung · 3 shared papers, 2019–2020 · strength 0.34
  18. Susannah G. Ellsworth · 3 shared papers, 2021–2022 · strength 0.30
  19. Waseem Lutfi · 2 shared papers, 2018 · strength 0.28
  20. Joal D. Beane · 2 shared papers, 2021 · strength 0.25
  21. Naomi H. Fei · 2 shared papers, 2020–2021 · strength 0.24
  22. Anthony Gebran · 1 shared paper, 2026 · strength 0.23
  23. Sebastiaan Ceuppens · 1 shared paper, 2026 · strength 0.23
  24. Jennifer Lee Miller-Ocuin · 3 shared papers, 2017–2020 · strength 0.22
  25. Lee Mayer Ocuin · 3 shared papers, 2017 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.